 Todos Medical Ltd has provided an update on its coronavirus COVID-19 oral antiviral 3CL protease inhibitor Tollovir clinical development program, which is currently enrolling in a Phase 2 clinical trial in hospitalized patients at Shaare Zedek Medical Center in Jerusalem. The company said it has begun a thorough re-evaluation of outpatient trial designs to provide the fastest path to bring Tollovir to market in the outpatient setting given the now significantly lower-than-expected patient enrollment threshold required to demonstrate efficacy. 